ClinicalTrials.gg

Program

sitagliptin

Also written as “Sitagliptin”, “sitagliptin phosphate” and “Sitagliptin phosphate”.

Its studies are mostly in Diabetes Mellitus, Type 2 · Diabetes Mellitus · Glucose Intolerance · Renal Insufficiency · Hepatic Insufficiency, led by 11 companies.

Furthest: phase 4, since Jan 28, 2009101 company-led studies, 2 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Merck780 open or runningphase 4since Jan 28, 2009Jul 2, 2004none ahead
Ono Pharmaceutical50 open or runningphase 3since Aug 11, 2006Aug 11, 2006none ahead
ADIUM40 open or runningno phasesince Aug 10, 2026Aug 10, 2026none ahead
Novo Nordisk40 open or runningphase 4since Jan 24, 2012Jun 18, 2008none ahead
Bio-innova22 open or runningphase 1since Dec 15, 2023Dec 15, 2023none ahead
Novartis20 open or runningphase 4since Sep 13, 2012Jun 12, 2012none ahead
Profil Institut für Stoffwechselforschung20 open or runningphase 2since Aug 28, 2013Aug 28, 2013none ahead
Chong Kun Dang Pharmaceutical10 open or runningphase 1since Jun 30, 2016Jun 30, 2016none ahead
dong-wha-pharmaceutical-co-ltd10 open or runningphase 1since May 4, 2022May 4, 2022none ahead
getz-pharma10 open or runningphase 4since Nov 29, 2021Nov 29, 2021none ahead
kinemed10 open or runningno phasesince Mar 23, 2010Mar 23, 2010none ahead

Also a collaborator on its studies: parexel, Pfizer, Bristol-Myers Squibb and Eli Lilly.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 42 studies since Aug 6, 2008.

  1. Jan 2, 2013Phase 3 study in Diabetes Mellitus, Type 2Merck · NCT01760447 · 223 enrolled
  2. Jul 22, 2013Phase 4 study in Diabetes MellitusNovo Nordisk · NCT01907854 · 407 enrolled · United States, Canada, Hungary and more
  3. Aug 28, 2013Profil Institut für Stoffwechselforschung's first study: phase 2 study in Diabetes Mellitus, Type 2New to Profil Institut für StoffwechselforschungProfil Institut für Stoffwechselforschung · NCT01936025 · 34 enrolled · Germany
  4. Mar 25, 2014Phase 3 study in Diabetes Mellitus, Type 2Merck · NCT02099110 · 1,233 enrolled
  5. Dec 12, 2014Phase 4 study in Diabetes Mellitus, Type 2Merck · NCT02318693 · 53 enrolled
  6. Aug 25, 2015Phase 3 study in Diabetes Mellitus, Type 2Merck · NCT02532855 · 614 enrolled
  7. Apr 11, 2016Phase 3 study in Diabetes Mellitus, Type 2Merck · NCT02738879 · 746 enrolled
  8. Jun 1, 2016Phase 3 study in Diabetes Mellitus, Type 2Merck · NCT02791490 · 458 enrolled
  9. Jun 30, 2016Chong Kun Dang Pharmaceutical's first study: phase 1 study in Diabetes Mellitus, Type 2New to Chong Kun Dang PharmaceuticalChong Kun Dang Pharmaceutical · NCT02827890 · 20 enrolled · Korea, Republic of
  10. Nov 24, 2017Phase 2 study in Pharmacological ActionProfil Institut für Stoffwechselforschung · NCT03359590 · 20 enrolled · Germany
  11. Nov 29, 2021getz-pharma's first study: phase 4 study in Diabetes Mellitus, Type 2New to getz-pharmagetz-pharma · NCT05167513 · 188 enrolled · Pakistan
  12. May 4, 2022dong-wha-pharmaceutical-co-ltd's first study: phase 1 study in Healthy SubjectsNew to dong-wha-pharmaceutical-co-ltddong-wha-pharmaceutical-co-ltd · NCT05403281 · 41 enrolled · Korea, Republic of
  13. Dec 15, 2023Bio-innova's first studies: 2 phase 1 studies in Healthy SubjectsNew to Bio-innovaBio-innova · NCT06233240, NCT06233201
  14. Aug 10, 2026ADIUM's first studies: 4 no phase studiesNew to ADIUMADIUM · NCT07763964, NCT07763951, NCT07763912 and 1 more

TargetBeta

DPP4 →read by rule
“Dipeptidyl peptidase IV inhibitor; Dipeptidyl peptidase IV inhibitor; Dipeptidyl peptidase IV inhibitor”ChEMBL 37, by rule

Other programs on DPP4

ProgramCompanyFurthest phaseStudies
LinagliptinruleBoehringer Ingelheimphase 496
gemigliptinruleLG Chemphase 430
anagliptinruleJW Pharmaceuticalphase 46
Empagliflozin/LinagliptinruleHumanis Saglık Anonim Sirketiphase 12
cofrogliptinruleHaisco Pharmaceutical Groupno phase1

Studies

The newest 60 of 101 led by companies developing it. Each opens its study page. Every study on its drug page →

StudyPhaseStatusLed byPrimary completionSize
NCT07763964Bioequivalance · Mexico–CompletedADIUMDec 19, 202546
NCT07763951Bioequivalance · Mexico–CompletedADIUMDec 14, 202546
NCT07763912Bioequivalence · Mexico–CompletedADIUMDec 5, 202546
NCT07763899Bioequivalance · Mexico–CompletedADIUMNov 30, 202546
NCT06233240Healthy Subjects1Not yet recruitingBio-innovaMay 29, 202434
NCT06233201Healthy Subjects1Not yet recruitingBio-innovaJul 14, 202434
NCT05403281Healthy Subjects · Korea, Republic of1Completeddong-wha-pharmaceutical-co-ltdDec 3, 202141
NCT05167513Diabetes Mellitus, Type 2 · Pakistan4Completedgetz-pharmaApr 28, 2022188
NCT03359590Pharmacological Action · Germany2CompletedProfil Institut für StoffwechselforschungJul 17, 201920
NCT02827890Diabetes Mellitus, Type 2 · Korea, Republic of1CompletedChong Kun Dang PharmaceuticalApr 201620
NCT02791490Diabetes Mellitus, Type 23CompletedMerckFeb 1, 2018458
NCT02738879Diabetes Mellitus, Type 23CompletedMerckJan 22, 2018746
NCT02532855Diabetes Mellitus, Type 23CompletedMerckOct 10, 2017614
NCT02318693Diabetes Mellitus, Type 24CompletedMerckDec 15, 201553
NCT02099110Diabetes Mellitus, Type 23CompletedMerckMay 26, 20161,233
NCT01936025Diabetes Mellitus, Type 2 · Germany2CompletedProfil Institut für StoffwechselforschungApr 201434
NCT01907854Diabetes Mellitus · United States, Canada, Hungary and more4CompletedNovo NordiskJun 15, 2015407
NCT01760447Diabetes Mellitus, Type 23CompletedMerckSep 17, 2019223
NCT01702298Diabetes Mellitus, Type 23CompletedMerckMay 29, 201342
NCT01686932Diabetes Mellitus, Type 2 · Germany4CompletedNovartisSep 201451
NCT01678820Diabetes Mellitus, Type 23TerminatedMerckNov 1, 2013299
NCT01619332Diabetes Mellitus, Type 2 · United States2CompletedNovartisSep 2013220
NCT01590797Diabetes Mellitus, Type 23CompletedMerckJun 11, 2014467
NCT01590771Diabetes Mellitus, Type 23CompletedMerckJun 10, 2014498
NCT01582308Diabetes Mellitus, Type 21CompletedMerckDec 4, 201222
NCT01557504Diabetes Mellitus, Type 21CompletedMerckApr 29, 201425
NCT01519674Diabetes Mellitus · Argentina, Australia, Brazil and more4CompletedNovo NordiskOct 2013582
NCT01485614Diabetes Mellitus3CompletedMerckOct 9, 2019200
NCT01477853Diabetes Mellitus, Type 23TerminatedMerckDec 4, 2012166
NCT01517321Diabetes Mellitus, Type 2 · Japan3CompletedOno Pharmaceutical
NCT01462266Diabetes Mellitus, Type 23CompletedMerckJun 6, 2013660
NCT01405911Glucose Intolerance2CompletedMerckApr 9, 2012242
NCT01340768Diabetes Mellitus, Type 23CompletedMerckSep 21, 2011870
NCT01296412Diabetes Mellitus, Type 23CompletedMerckFeb 29, 2012653
NCT01189890Diabetes Mellitus, Type 23CompletedMerckOct 31, 2012480
NCT01177384Diabetes Mellitus, Type 23CompletedMerckMar 25, 2013380
NCT01131182Diabetes Mellitus, Type 24CompletedMerckNov 4, 20101,147
NCT01092663Diabetes Mellitus, Type 2 · United States–CompletedkinemedJul 201161
NCT01093794Diabetes Mellitus, Type 21CompletedMerckJun 201028
NCT01076088Diabetes Mellitus, Type 23CompletedMerckDec 24, 2012744
NCT01076075Diabetes Mellitus, Type 23CompletedMerckJul 11, 2011427
NCT01046110Diabetes Mellitus · United States, Argentina, Canada and more3CompletedNovo NordiskNov 2010458
NCT01034111Diabetes Mellitus, Type 23CompletedMerckOct 4, 201030
NCT01028391Diabetes Mellitus, Type 23CompletedMerckJan 1, 2009317
NCT00993187Diabetes Mellitus, Type 24CompletedMerckOct 29, 2013292
NCT00975052Diabetes Mellitus, Type 21CompletedMerckMar 200616
NCT00944450Diabetes Mellitus, Type 21CompletedMerckSep 200412
NCT00929201Diabetes Mellitus, Type 21CompletedMerckMar 200861
NCT00888238Diabetes Mellitus, Type 21CompletedMerckJun 10, 200912
NCT00885352Diabetes Mellitus, Type 23CompletedMerckNov 10, 2010313
NCT00875394Diabetes Mellitus, Type 23CompletedMerckJun 27, 200868
NCT00854035Diabetes Mellitus, Type 2 · Japan3CompletedOno PharmaceuticalJun 2010266
NCT00833027Diabetes Mellitus4CompletedMerckOct 30, 2009608
NCT00832624Diabetes Mellitus, Type 24TerminatedMerckSep 2, 200910
NCT00832390Diabetes Mellitus4CompletedMerckJul 11, 200829
NCT00830076Diabetes Mellitus, Type 21CompletedMerckApr 30, 200918
NCT00813995Diabetes Mellitus, Type 23CompletedMerckAug 9, 2010395
NCT00790205Diabetes Mellitus, Type 23CompletedMerckMar 30, 201514,671
NCT00758069Diabetes Mellitus, Type 22CompletedMerckFeb 13, 200680
NCT00730275Diabetes Mellitus, Type 21CompletedMerckDec 30, 201035

How it is read

Names in the registry

  • “Sitagliptin”, 33 entries
  • “sitagliptin phosphate”, 18 entries
  • “sitagliptin”, 15 entries
  • “Sitagliptin phosphate”, 10 entries
  • “Sitagliptin/Metformin FDC”, 5 entries

Codes read as this program: MK0431.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.